C4X Discovery Holdings plc

Biotech initial public offerings in Europe have been as rare as hen’s teeth in the past few years so the news that Swiss antibiotics specialist BioVersys is looking to list has caught the eye. The Bas

UK company C4X Discovery Holdings plc has used its proprietary PatientSeek platform to identify in patients a genetic response signature that separates responders and non-responders to vedolizumab,

Destiny Pharma plc is set to become the latest UK biotech to bid farewell to the London Stock Exchange’s Alternative Investment Market (AIM) and will take the private route to access cash for its lat

The UK's e-Therapeutics plc has become the latest biotech to quit the London Stock Exchange’s Alternative Investment Market (AIM), with CEO Ali Mortazavi slamming the lack of risk the country's inve